Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-01-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2010-04-279760PMID 21097672PMCID PMC4009699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Myeloma cell‐induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast‐myeloma hybrid cells

  2010cited by this paper
• Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

  2009cited by this paper
• An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization.

  2009cited by this paper
• Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma

  2009cited by this paper
• Myeloma bone disease: recent advances in biology, diagnosis, and treatment.

  2009cited by this paper
• Bone marrow microenvironment and the identification of new targets for myeloma therapy

  2009cited by this paper
• Chemokine signaling in cancer: one hump or two?

  2009cited by this paper
• The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

  2009cited by this paper
• Apoptosis of Human Primary Osteoclasts Treated with Molecules Targeting Nuclear Factor‐κB

  2009cited by this paper
• A physical mechanism for coupling bone resorption and formation in adult human bone.

  2008cited by this paper
• How chemokines invite leukocytes to dance

  2008cited by this paper
• Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate

  2008cited by this paper
• Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

  2008cited by this paper
• A new method for class prediction based on signed-rank algorithms applied to Affymetrix® microarray experiments

  2008cited by this paper
• The pathogenesis of the bone disease of multiple myeloma.

  2008cited by this paper
• TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

  2007cited by this paper
• Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin

  2007cited by this paper
• Pax5: the guardian of B cell identity and function

  2007cited by this paper
• Bone marrow mesenchymal stem cells are abnormal in multiple myeloma

  2007cited by this paper
• MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

  2007cited by this paper
• Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

  2007cited by this paper
• Microarray‐based understanding of normal and malignant plasma cells

  2006cited by this paper
• The many roles of chemokines and chemokine receptors in inflammation.

  2006cited by this paper
• Chemokines in multiple myeloma.

  2006cited by this paper
• New Potential Targets for Treating Myeloma Bone Disease

  2006cited by this paper
• Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

  2006cited by this paper
• Remodeling and Vascular Spaces in Bone

  2006cited by this paper
• Role of IGF‐I Signaling in Regulating Osteoclastogenesis

  2006cited by this paper
• Myeloma bone disease

  2005cited by this paper
• MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

  2005cited by this paper
• MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells

  2005cited by this paper
• Proteolytic Activation of Alternative CCR1 Ligands in Inflammation1

  2005cited by this paper
• The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

  2005cited by this paper
• Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.

  2004cited by this paper
• BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

  2004cited by this paper
• Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells

  2004cited by this paper
• Cancer and the Microenvironment

  2004cited by this paper
• Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.

  2003cited by this paper
• Receptor activator of NF‐κB ligand, macrophage inflammatory protein‐1α, and the proteasome

  2003cited by this paper
• Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3

  2003cited by this paper
• Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

  2003cited by this paper
• Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

  2003cited by this paper
• Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma.

  2002cited by this paper
• Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

  2002cited by this paper
• Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.

  2002cited by this paper
• Myeloma bone disease.

  2001cited by this paper
• Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease.

  2001cited by this paper
• Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.

  2001cited by this paper
• Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease

  2001cited by this paper
• Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

  2001cited by this paper
• Cancellous Bone Remodeling Occurs in Specialized Compartments Lined by Cells Expressing Osteoblastic Markers

  2001cited by this paper
• Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors

  2000cited by this paper
• Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop.

  1996cited by this paper
• Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.

  1995cited by this paper
• Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

  1991cited by this paper

• Characteristics of osteoclasts at different developmental stages and therapeutic strategies.

  2026cites this paper
• Overcoming Microenvironment-Driven Resistance to CAR-T Therapy in Multiple Myeloma

  2026cites this paper
• The Importance of Chemokines Activating CXCR1, CXCR2 and CXCR3 in Tumorigenesis as Potential Therapeutic Targets in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

  2025cites this paper
• Mer receptor expression promotes multiple myeloma disease development via a cell-extrinsic mechanism.

  2025cites this paper
• PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

  2025cites this paper
• Phenolic acids prevent sex-steroid deficiency-induced bone loss and bone marrow adipogenesis in mice.

  2024cites this paper
• Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment

  2024cites this paper
• Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma

  2024cites this paper
• Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics

  2023cites this paper
• Glia maturation factor beta deficiency protects against diabetic osteoporosis by suppressing osteoclast hyperactivity

  2023cites this paper
• Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche

  2022influential citation
• Effect of teriparatide on drug treatment of tuberculous spondylitis: an experimental study

  2022cites this paper
• Comprehensive characterization of the epigenetic landscape in Multiple Myeloma

  2022cites this paper
• Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma

  2021cites this paper
• CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

  2021cites this paper
• Comprehensive characterization of the epigenetic landscape in Multiple 1 Myeloma 2

  2021cites this paper
• RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma

  2021cites this paper
• Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients

  2021cites this paper
• Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.

  2021cites this paper
• Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo

  2020cites this paper
• Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma

  2020influential citation
• Implication of the Association of Fibrinogen Citrullination and Osteoclastogenesis in Bone Destruction in Rheumatoid Arthritis

  2020cites this paper
• Multiple Myeloma: Methods and Protocols

  2020cites this paper
• Hippuric acid and 3‐(3‐hydroxyphenyl) propionic acid inhibit murine osteoclastogenesis through RANKL‐RANK independent pathway

  2019cites this paper
• Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo

  2019cites this paper
• Chemokines in Physiological and Pathological Bone Remodeling

  2019cites this paper
• Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma

  2019cites this paper
• Correlation between high serum alkaline phosphatase levels and denosumab‐related hypocalcemia in patients with multiple myeloma

  2019cites this paper
• OTT_A_192490 8467..8478

  2019cites this paper
• Analysis of Global Gene Expression Profiles.

  2018cites this paper
• Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

  2018cites this paper
• Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets

  2018cites this paper
• MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento‐ossifying fibroma

  2018cites this paper
• Oncostatin M promotes the osteogenic differentiation of mouse MC3T3-E1osteoblasts through the regulation of monocyte chemotactic protein-1

  2018cites this paper
• Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

  2018cites this paper
• Practical Considerations for Bone Health in Multiple Myeloma

  2018cites this paper
• Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion

  2017cites this paper
• Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments

  2017cites this paper
• Personalized Therapy for Multiple Myeloma

  2017cites this paper
• Aalborg Universitet Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients

  2016cites this paper
• Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease.

  2016cites this paper
• Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients

  2016cites this paper
• Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

  2016cites this paper
• APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

  2016cites this paper
• LYMPHOID NEOPLASIA APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

  2016cites this paper
• Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis.

  2015cites this paper
• Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma

  2015cites this paper
• Treatment of multiple myeloma bone disease: experimental and clinical data

  2015cites this paper
• Contribution of osteoclasts to the bone–tumor niche

  2015cites this paper
• NF-κB-direct activation of microRNAs with repressive effects on monocyte-specific genes is critical for osteoclast differentiation

  2015cites this paper
• Myeloma and osteoclast relationship

  2015cites this paper
• The Role of Chemoattractant Receptors in Shaping the Tumor Microenvironment

  2014cites this paper
• Ossäre Manifestationen des multiplen Myeloms

  2014cites this paper
• RATIONALE FOR A NOTCH-DIRECTED THERAPY TO PREVENT MULTIPLE MYELOMA CROSSTALK WITH THE OSTEOCLASTOGENIC NICHE

  2014cites this paper
• Management of bone disease in multiple myeloma

  2014cites this paper
• The expression of MCP-1 and CCR2 in induced rats periapical lesions.

  2014cites this paper
• MCP‐1 as a Potential Target to Inhibit the Bone Invasion by Oral Squamous Cell Carcinoma

  2014cites this paper
• Notch signaling drives multiple myeloma induced osteoclastogenesis

  2014cites this paper
• Comparative transcriptomics reveals RhoE as a novel regulator of actin dynamics in bone-resorbing osteoclasts

  2014cites this paper
• MCP-1 Expression Is Specifically Regulated During Activation of Skeletal Repair and Remodeling

  2013cites this paper
• Relationship between Circulating BAFF Serum Levels with Proliferating Markers in Patients with Multiple Myeloma

  2013cites this paper
• BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma

  2013cites this paper
• The Role of APRIL in Promoting Cell Cycle Progression and Drug Resistance in Multiple Myeloma

  2013cites this paper
• MOLECULAR MECHANISMS OF THROMBOXANE A2 RECEPTOR-MEDIATED INVASION IN LUNG CANCER CELLS

  2012cites this paper
• CCR2 (chemokine (C-C motif) receptor 2)

  2012cites this paper
• Clinical utility and implementation of gene-expression profiling in myeloma: current status and challenges

  2012cites this paper
• Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma

  2012cites this paper
• Università degli Studi di Milano Scuola di Dottorato in Medicina Molecolare

  2012cites this paper
• Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?

  2012cites this paper
• Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

  2011cites this paper